RESUMEN
BACKGROUND: There is extensive evidence to show that pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate (TDF)-based formulations dramatically reduces the risk of HIV acquisition among individuals without HIV infection. Here, the authors aim to compare tenofovir plasma predose concentrations in subjects taking PrEP daily versus on demand and using different TDF-based generic formulations. METHODS: Subjects providing informed signed consent for the measurement of tenofovir plasma levels were included in the study. Predose drug concentrations were stratified according to PrEP administration and the type of TDF-based formulation. The control group consisted of patients with HIV infection who were matched for renal function and were administered branded TDF that was not combined with boosted-antiretroviral drugs. RESULTS: The study consisted of 100 subjects (mean age, 39 ± 10 years; body weight, 77 ± 11 kg). A wide distribution in tenofovir predose concentrations was observed, with values ranging from 17 to 297 ng/mL (coefficient of variation 77%). No significant differences were noted in tenofovir predose concentrations between subjects who were administered PrEP daily (n = 75) or on demand (n = 25) [94 (35-255) versus 104 (37-287) ng/mL; P = 0.476]. Comparable tenofovir predose concentrations were found between patients with HIV infection (n = 220) who were administered branded TDF and those without HIV infection who were treated with 5 different generic TDF-based formulations with generics-to-branded ratios. These were always within the range of 80%-125% and were used to define bioequivalence. CONCLUSIONS: The marketed generic formulations of TDF delivered tenofovir plasma predose concentrations comparable with those delivered by branded formulations.
Asunto(s)
Fármacos Anti-VIH/sangre , Medicamentos Genéricos/metabolismo , Tenofovir/sangre , Adulto , Fármacos Anti-VIH/uso terapéutico , Femenino , Infecciones por VIH/sangre , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Profilaxis Pre-Exposición/métodos , Estudios Retrospectivos , Tenofovir/uso terapéuticoRESUMEN
Background Indonesian Ministry of Health advocate doctors, especially in government-owned healthcare facility, to prescribe generic drugs including amoxicillin. Although BPOM (the National Agency of Drug and Food Control) already guarantees that the generic amoxicillin and the branded one were interchangeable, lack of confidence in generic drugs still remains among patients, pharmacists, and doctors. This issue supported by lack of publication confirmed the therapeutic equivalence of branded and generic drugs. This study aims to evaluate and compare the in vitro microbiological assay of different generic and branded amoxicillin that are available in Indonesian market, especially those used in government-owned healthcare facilities. Methods Microbiological assays for five samples of amoxicillin tablet containing 500 mg amoxicillin available in Indonesia were determined using a method from Indonesia Pharmacopeia. Samples were coded as Products A to E. The assay was carried out by measuring the diameter of the inhibition zones in the plate agar incubated with Escherichia coli and Staphylococcus aureus. The obtained data were evaluated to determine the sample potency and compared with the amoxicillin reference standard. Results Minor and insignificant differences (p > 0.05) were found in the diameters of the inhibition zones. Potency ratio measured both in E. coli and S. aureus were all between 95% and 105%. The lowest of the tested samples were from Product C, which resulted to ratio potencies of 96.3% and 95.5% in E. coli and S. aureus, respectively. Conclusions All five samples were in the range of the acceptance criteria. Therefore, from the view of the microbiological assay, these products are in equivalence in quality and are interchangeable.
Asunto(s)
Amoxicilina/farmacología , Antibacterianos/farmacología , Medicamentos Genéricos/farmacología , Escherichia coli/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/métodos , Staphylococcus aureus/efectos de los fármacos , Equivalencia Terapéutica , Amoxicilina/química , Amoxicilina/metabolismo , Antibacterianos/química , Antibacterianos/metabolismo , Medicamentos Genéricos/química , Medicamentos Genéricos/metabolismo , Humanos , Técnicas In Vitro , ComprimidosRESUMEN
INTRODUCTION: Due to the chaos in the legislation in the Middle East, male enhancement nutraceuticals may be sold without any registration or evaluation. These products need to be evaluated with respect to safety and efficacy. Furthermore, cultural and social considerations in the Middle East prevent the use of international evaluations schemes for erectile dysfunction. AIM: Evaluating the safety and efficacy parameters of generic and nutraceutical products for erectile dysfunction in the Middle East through a custom-designed, representable and simple system tailored to the regional culture. METHODS: 74 healthy male volunteers were enrolled into a comparative, simple randomized, single dose, double blind, and crossover clinical study incorporated with a tailored-designed questionnaire. Safety assessment included laboratory analysis for liver functions and measuring blood pressure. MAIN OUTCOME MEASURES: Subjective data regarding safety and efficacy were assessed from the validated questionnaire. Blood pressure was measured. Blood samples were collected to assess the drug/adulterants concentration and liver and kidney functions. RESULTS: All tested nutraceuticals showed undeclared Sildenafil citrate in patients. Questionnaire results showed high inter-patient variability with respect to efficacy and comparable safety profile compared to Viagra®. CONCLUSION: The validated tailored-designed questionnaire effectively assessed the efficacy and safety of male enhancement products. The male enhancement nutraceuticals, sold in Egypt, claimed to be 100% natural are adulterated and of questionable safety profile.
Asunto(s)
Suplementos Dietéticos/análisis , Contaminación de Medicamentos , Medicamentos Genéricos/análisis , Disfunción Eréctil/sangre , Disfunción Eréctil/epidemiología , Citrato de Sildenafil/análisis , Adulto , Estudios Cruzados , Método Doble Ciego , Contaminación de Medicamentos/prevención & control , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/uso terapéutico , Egipto/epidemiología , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Fosfodiesterasa 5/análisis , Inhibidores de Fosfodiesterasa 5/sangre , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Citrato de Sildenafil/sangre , Citrato de Sildenafil/uso terapéutico , Resultado del TratamientoRESUMEN
In this study, brand and four generic formulations of telmisartan, an antihypertensive drug, were used in in vitro simultaneous dissolution-absorption, investigating the effect of different formulation additives on dissolution and on absorption through an artificial membrane. The in vitro test was found to be sensitive enough to show even small differences between brand and generic formulations caused by the use of different excipients. By only changing the type of filler from sorbitol to mannitol in the formulation, the flux through the membrane was reduced by approximately 10%. Changing the salt forming agent as well resulted in approximately 20% of flux reduction compared to the brand formulation. This significant difference was clearly shown in the published in vivo results as well. The use of additional lactose monohydrate in the formulation also leads to approximately 10% reduction in flux. The results show that by changing excipients, the dissolution of telmisartan was not altered significantly, but the flux through the membrane was found to be significantly changed. These results pointed out the limitations of traditional USP dissolution tests and emphasized the importance of simultaneously measuring dissolution and absorption, which allows the complex effect of formulation excipients on both processes to be measured. Moreover, the in vivo predictive power of the simultaneous dissolution-absorption test was demonstrated by comparing the in vitro fluxes to in vivo bioequivalence study results.
Asunto(s)
Bencimidazoles/química , Bencimidazoles/metabolismo , Benzoatos/química , Benzoatos/metabolismo , Liberación de Fármacos , Medicamentos Genéricos/química , Medicamentos Genéricos/metabolismo , Antihipertensivos/química , Antihipertensivos/metabolismo , Disponibilidad Biológica , Composición de Medicamentos , Liberación de Fármacos/fisiología , Membranas Artificiales , Solubilidad , TelmisartánRESUMEN
BACKGROUND: The aim of this study was to compare the bioavailability of a new generic formulation of oseltamivir 75-mg capsule (test) and a branded formulation Tamiflu® (reference) to meet regulatory criteria for marketing the test product in healthy Chinese male volunteers. METHODS: This single-dose, randomized-sequence, open-label, two-period crossover study was conducted in fasted healthy Chinese male volunteers, who first received a single oral dose of the test or reference formulation with a 7-day washout period, and then the alternative formulation. The study drug was administered after a 10-hour overnight fast. Blood samples were collected at baseline and at 0.25, 0.5, 0.75, 1.0, 1.5, 2, 4, 6, 8, 10, 12, 24, and 36 hours after administration of the study drug. Plasma concentrations of the parent oseltamivir and its metabolite oseltamivir carboxylate were determined using an LC-MS/MS method. The formulations were considered bioequivalent if the 90% confidence intervals (CIs) for the log-transformed values were within the predetermined equivalence range (70 - 143% for Cmax, 80 - 125% for AUC) according to the guidelines of the State Food and Drug Administration of China. Adverse events (AEs) were monitored throughout the study based on clinical parameters and patient reports. RESULTS: Characteristics of the 20 male volunteers included were as follows: mean age 23 (± 0.7, SD) years (range 21 - 24 years); weight 69 (± 7.1) kg (range 60 - 88 kg); height 177 (± 5.9) cm (range 168 - 192 cm). All included subjects completed the study. The mean geometric ratio between the test and reference formulations of oseltamivir was 99.5% (90% CI), 86.3 - 114.8%) for Cmax, 104.4% (95.7 - 113.9%) for AUC0-t, and 104.4% (95.6 - 113.9%) for AUC0-∞. That of oseltamivir carboxylate was 103.7% (90% CI, 95.3 - 112.8%) for Cmax, 101.7% (96.6 - 107.1%) for AUC0-t, and 101.4% (96.5 - 106.5%) for AUC0-∞. There was no significant difference in pharmacokinetic parameters between the two groups. Only 1 AE (nausea) occurred in 1 subject who received the test formulation; the AE resolved without any treatment. CONCLUSIONS: The result of this single-dose study indicated that the test formulation of oseltamivir capsule met the Chinese regulatory criteria for bioequivalence vs. the reference formulation in fasted healthy Chinese male volunteers.â©.
Asunto(s)
Oseltamivir/metabolismo , Oseltamivir/farmacocinética , Adulto , Área Bajo la Curva , Pueblo Asiatico , Disponibilidad Biológica , Cápsulas/metabolismo , Cápsulas/farmacocinética , Química Farmacéutica/métodos , Estudios Cruzados , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/farmacocinética , Voluntarios Sanos , Humanos , Masculino , Oseltamivir/análogos & derivados , Equivalencia Terapéutica , Adulto JovenRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Antidepresivos/administración & dosificación , Antidepresivos/uso terapéutico , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/uso terapéutico , Farmacovigilancia , Antidepresivos Tricíclicos/uso terapéutico , Psicotrópicos/clasificación , Psicotrópicos/farmacologíaRESUMEN
Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US. Clozapine is available as tablets in all countries, as an oral suspension in all included countries, with the exception of Japan and Romania, as orally disintegrating tablets in the US and China, and as an injectable in The Netherlands. General practitioner prescribing is only available in The Netherlands, New Zealand, the UK and the US, although with some restrictions in some of the countries. In Ireland and China, clozapine is only dispensed through hospital pharmacies. Hematological monitoring is mandatory in all countries but varies substantially in frequency, e.g. in Denmark hematologic monitoring is mandatory weekly for 18 weeks, followed by monthly monitoring, compared with Japan where blood work is required weekly for 26 weeks, followed by biweekly hematologic monitoring thereafter. In most included countries, with the exception of Denmark, Romania and The Netherlands, the manufacturer provides a mandatory hematological monitoring database, and dispensing of clozapine is not permissible without acceptable white blood count and absolute neutrophil count results. Local guidelines in New Zealand recommend echocardiography and routine troponin during the initial phases of treatment with clozapine. Regulations of clozapine vary widely with regard to rules of prescribing and monitoring. A worldwide update and harmonization of these regulations is recommended.
Asunto(s)
Antipsicóticos/uso terapéutico , Clozapina/uso terapéutico , Control de Medicamentos y Narcóticos , Internacionalidad , Antipsicóticos/sangre , Clozapina/sangre , Monitoreo de Drogas/métodos , Resistencia a Medicamentos , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/uso terapéutico , Humanos , Esquizofrenia/sangre , Esquizofrenia/tratamiento farmacológicoRESUMEN
Biosimilars are required to be similar or highly similar in structure to their biologic reference product but are neither expected nor required to contain identical active substances. For example, glycosylated biosimilars approved to date demonstrate quantitative and qualitative structural differences from their reference product and exemplify the latitude of variations permitted for biosimilars. Although differences between a candidate biosimilar and its reference product will be evaluated for differential clinical effects during biosimilarity assessment, it is unlikely that potential differences between any two indirectly related biosimilars will be formally evaluated. Furthermore, biosimilar pathways permit variations in pharmaceutical attributes, clinical development approaches, and regulatory outcomes, resulting in further diversity of attributes among approved biosimilars. Because biosimilars may vary across the ranges of structural and functional acceptance criteria, they should not be treated like multisource, generic drugs.
Asunto(s)
Biosimilares Farmacéuticos/síntesis química , Diseño de Fármacos , Descubrimiento de Drogas/métodos , Animales , Biosimilares Farmacéuticos/economía , Biosimilares Farmacéuticos/metabolismo , Aprobación de Drogas/métodos , Descubrimiento de Drogas/economía , Descubrimiento de Drogas/legislación & jurisprudencia , Medicamentos Genéricos/síntesis química , Medicamentos Genéricos/economía , Medicamentos Genéricos/metabolismo , Epoetina alfa/síntesis química , Epoetina alfa/economía , Epoetina alfa/metabolismo , HumanosRESUMEN
In this study, the data of 113 human bioequivalence (BE) studies of immediate release (IR) formulations of 74 active pharmaceutical ingredients (APIs) conducted at Sawai Pharmaceutical Co., Ltd., was analyzed to understand the factors affecting intra- and intersubject variabilities in oral drug absorption. The ANOVA CV (%) calculated from area under the time-concentration curve (AUC) in each BE study was used as an index of intrasubject variability (Vintra), and the relative standard deviation (%) in AUC was used as that of intersubject variability (Vinter). Although no significant correlation was observed between Vintra and Vinter of all drugs, Vintra of class 3 drugs was found to increase in association with a decrease in drug permeability (P(eff)). Since the absorption of class 3 drugs was rate-limited by the permeability, it was suggested that, for such drugs, the low P(eff) might be a risk factor to cause a large intrasubject variability. To consider the impact of poor water solubility on the variability in BE study, a parameter of P(eff)/Do (Do; dose number) was defined to discriminate the solubility-limited and dissolution-rate-limited absorption of class 2 drugs. It was found that the class 2 drugs with a solubility-limited absorption (P(eff)/Do < 0.149 × 10(-4) cm/s) showed high intrasubject variability. Furthermore, as a reason for high intra- or intersubject variability in AUC for class 1 drugs, effects of drug metabolizing enzymes were investigated. It was demonstrated that intrasubject variability was high for drugs metabolized by CYP3A4 while intersubject variability was high for drugs metabolized by CYP2D6. For CYP3A4 substrate drugs, the Km value showed the significant relation with Vintra, indicating that the affinity to the enzyme can be a parameter to predict the risk of high intrasubject variability. In conclusion, by analyzing the in house data of human BE study, low permeability, solubility-limited absorption, and high affinity to CYP3A4 are identified as risk factors for high intrasubject variability in oral drug absorption. This information is of importance to design the human BE study for oral drug products containing APIs with a risk of large intrasubject variability in oral absorption.
Asunto(s)
Medicamentos Genéricos/metabolismo , Administración Oral , Área Bajo la Curva , Química Farmacéutica/métodos , Simulación por Computador , Humanos , Absorción Intestinal/fisiología , Modelos Biológicos , Permeabilidad , Solubilidad , Equivalencia TerapéuticaRESUMEN
Nanomedicines are more complex than most pharmacologically active substances or medicines and have been considered as non-biological complex drugs. For nanomedicines pivotal pharmacokinetic properties cannot be assessed by plasma concentration data from standard bioequivalence studies. Using intravenous iron complexes (IICs) as model we show that fetal avian tissues can be used to study time dependent tissue concentrations in heart and liver. Clear differences were found between equimolar doses of sucrose, gluconate or carboxymaltose coated iron particles. The range in tissue iron concentrations observed with these clinically widely used IICs provides an orientation as to what should be acceptable for any new IICs. Moreover, sensitivity of the experimental model was high enough to detect a 20% difference in tissue iron concentration. For the authorization of generic products under Article 10 (1) of Directive 2001/83/EC a plasma concentration of an active substance in the range of 80%-125% versus the reference product is usually considered acceptable. Based on its high discriminatory sensitivity this method was used to support a positive marketing authorization decision for a generic nanomedicine product.
Asunto(s)
Pollos/metabolismo , Corazón/fisiología , Compuestos de Hierro/metabolismo , Hierro/metabolismo , Hígado/metabolismo , Distribución Tisular/fisiología , Administración Intravenosa , Animales , Medicamentos Genéricos/administración & dosificación , Medicamentos Genéricos/metabolismo , Hierro/administración & dosificación , Compuestos de Hierro/administración & dosificación , Nanomedicina/métodos , Equivalencia TerapéuticaRESUMEN
CONTEXT: Severe iron deficiency requires intravenous iron supplementation to replenish iron stores. Intravenous iron sucrose has been used for decades for the treatment of anemia. New generic iron sucrose products are now marketed for the use in several countries and there is an ongoing discussion about the safety and efficacy of iron sucrose similars. OBJECTIVE: In this study, we compared the iron sucrose originator Venofer® and the generic iron sucrose AZAD (ISA) regarding bioavailability, toxicity and stability in human THP-1 cells and HepG2 cells. METHODS: The bioavailability of Venofer® and ISA was investigated in both cell types by a ferrozin-based assay. The release of incorporated iron was assayed by atomic absorption spectroscopy. Ferritin content was measured by enzyme-linked immunosorbent assay (ELISA). HepG2 cells were used to investigate the intracellular labile iron pool (LIP), which was measured by the fluorescent calcein assay. The amount of redox-active iron within the iron formulations was assayed using fluorescent dichlorofluorescein. RESULTS: We found no significant differences in all parameters between Venofer® and ISA in regard of bioavailability, toxicity and stability in vitro. DISCUSSION: ISA shows identical physico-chemical features and identical bioavailability in vitro. This study is a profound basis for future clinical tests with generic iron sucrose compounds.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Medicamentos Genéricos/administración & dosificación , Medicamentos Genéricos/química , Compuestos Férricos/administración & dosificación , Compuestos Férricos/química , Sacarosa/administración & dosificación , Sacarosa/química , Disponibilidad Biológica , Técnicas de Cultivo de Célula , Relación Dosis-Respuesta a Droga , Liberación de Fármacos , Estabilidad de Medicamentos , Medicamentos Genéricos/efectos adversos , Medicamentos Genéricos/metabolismo , Ensayo de Inmunoadsorción Enzimática , Compuestos Férricos/efectos adversos , Compuestos Férricos/metabolismo , Sacarato de Óxido Férrico , Ferritinas/metabolismo , Ácido Glucárico , Células Hep G2 , Humanos , Inyecciones Intravenosas , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Espectrofotometría Atómica , Sacarosa/efectos adversos , Sacarosa/metabolismoRESUMEN
The effect of process variability on physicochemical characteristics and in vitro performance of qualitatively (Q1) and quantitatively (Q2) equivalent generic acyclovir topical dermatological creams was investigated to develop a matrix of standards for determining their in vitro bioequivalence with reference listed drug (RLD) product (Zovirax®). A fractional factorial design of experiment (DOE) with triplicate center point was used to create 11 acyclovir cream formulations with manufacturing variables such as pH of aqueous phase, emulsification time, homogenization speed, and emulsification temperature. Three more formulations (F-12-F-14) with drug particle size representing RLD were also prepared where the pH of the final product was adjusted. The formulations were subjected to physicochemical characterization (drug particle size, spreadability, viscosity, pH, and drug concentration in aqueous phase) and in vitro drug release studies against RLD. The results demonstrated that DOE formulations were structurally and functionally (e.g., drug release) similar (Q3) to RLD. Moreover, in vitro drug permeation studies showed that extent of drug bioavailability/retention in human epidermis from F-12-F-14 were similar to RLD, although differed in rate of permeation. The results suggested generic acyclovir creams can be manufactured to obtain identical performance as that of RLD with Q1/Q2/Q3.
Asunto(s)
Aciclovir/metabolismo , Antivirales/metabolismo , Aprobación de Drogas/métodos , Medicamentos Genéricos/metabolismo , Epidermis/metabolismo , Crema para la Piel/metabolismo , Aciclovir/análisis , Aciclovir/química , Antivirales/análisis , Antivirales/química , Cadáver , Fenómenos Químicos , Composición de Medicamentos , Medicamentos Genéricos/análisis , Medicamentos Genéricos/química , Emulsiones , Epidermis/química , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Tamaño de la Partícula , Permeabilidad , Crema para la Piel/química , Solubilidad , Temperatura de Transición , Estados Unidos , United States Food and Drug Administration , ViscosidadRESUMEN
In the proper use of medicine, the quality of medical supplies is an important factor. Use of generic products not only reduces drug costs for the patient, but also offers substantial advantages for governments in reducing medical expenses. When evaluation of the quality of generic products is centered on tablets, products with qualities that are unstable over time may be encountered. Some dosage forms require suitable pharmaceutical tests, processes, and apparatuses, such as those for evaluating orally disintegrating tablets or cutaneous preparations. For example, although simple test equipment has been proposed for patches, a unified method is required. The pharmacist plays an important role in choosing high-quality generic products; however, a substantial amount of information needs to be made available to the public in order to achieve that goal.
Asunto(s)
Química Farmacéutica/métodos , Medicamentos Genéricos/química , Medicamentos Genéricos/metabolismo , Humanos , Rol Profesional , Control de Calidad , Piel/metabolismoRESUMEN
Several studies with animal models have demonstrated that bioequivalence of generic products of antibiotics like vancomycin, as currently defined, do not guarantee therapeutic equivalence. However, the amounts and characteristics of impurities and degradation products in these formulations do not violate the requirements of the U.S. Pharmacopeia (USP). Here, we provide experimental data with three generic products of meropenem that help in understanding how these apparently insignificant chemical differences affect the in vivo efficacy. Meropenem generics were compared with the innovator in vitro by microbiological assay, susceptibility testing, and liquid chromatography/mass spectrometry (LC/MS) analysis and in vivo with the neutropenic guinea pig soleus infection model (Pseudomonas aeruginosa) and the neutropenic mouse thigh (P. aeruginosa), brain (P. aeruginosa), and lung (Klebisella pneumoniae) infection models, adding the dihydropeptidase I (DHP-I) inhibitor cilastatin in different proportions to the carbapenem. We found that the concentration and potency of the active pharmaceutical ingredient, in vitro susceptibility testing, and mouse pharmacokinetics were identical for all products; however, two generics differed significantly from the innovator in the guinea pig and mouse models, while the third generic was therapeutically equivalent under all conditions. Trisodium adducts in a bioequivalent generic made it more susceptible to DHP-I hydrolysis and less stable at room temperature, explaining its therapeutic nonequivalence. We conclude that the therapeutic nonequivalence of generic products of meropenem is due to greater susceptibility to DHP-I hydrolysis. These failing generics are compliant with USP requirements and would remain undetectable under current regulations.
Asunto(s)
Antibacterianos/farmacocinética , Dipeptidasas/metabolismo , Medicamentos Genéricos/farmacocinética , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Tienamicinas/farmacocinética , Animales , Antibacterianos/metabolismo , Biotransformación , Encéfalo/efectos de los fármacos , Encéfalo/microbiología , Cilastatina/farmacología , Dipeptidasas/antagonistas & inhibidores , Estabilidad de Medicamentos , Medicamentos Genéricos/metabolismo , Proteínas Ligadas a GPI/antagonistas & inhibidores , Proteínas Ligadas a GPI/metabolismo , Cobayas , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/fisiología , Pulmón/efectos de los fármacos , Pulmón/microbiología , Meropenem , Ratones , Pruebas de Sensibilidad Microbiana , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/microbiología , Inhibidores de Proteasas/farmacología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/fisiología , Equivalencia Terapéutica , Tienamicinas/metabolismo , Muslo/microbiología , Resultado del TratamientoRESUMEN
Los genéricos son a veces objeto de dudas y malentendidos por parte del médico o del paciente. En el caso del paciente con enfermedad de Alzheimer, el «baile» de genéricos puede ser un motivo de preocupación y causar problemas en la identificación del tratamiento habitual. Sin embargo, la eficacia y la seguridad del medicamento genérico están perfectamente avaladas al haberse demostrado su bioequivalencia con el medicamento innovador o de referencia. La bioequivalencia tiene como base una metodología cuyo fundamento es garantizar no solo que el medicamento genérico tiene la misma cantidad de principio activo que el medicamento de referencia, sino también que se absorbe exactamente del mismo modo, lo que permite asumir que producirá los mismos efectos sistémicos. El menor precio del genérico está sujeto a diversos factores, pero no se debe a diferencias en calidad, ya que su fabricación cumple con idénticos estándares a los del medicamento de referencia. Algunos conceptos relevantes en este campo son los de «prescribilidad », intercambiabilidad y políticas de sustitución. Así, un medicamento genérico autorizado puede ser prescrito con las mismas garantías de calidad, eficacia y seguridad que el medicamento de referencia y se debe considerar intercambiable, si bien es preferible evitar sustituciones innecesarias en los pacientes (AU)
The use of generic drugs is often surrounded by misunderstandings and questions, from patients and physicians. The switch between generic drugs is frequently a concern because it can difficult the ability of Alzheimers patients to recognize their daily medication. The efficacy and safety of a generic drug is fully endorsed by demonstrating its bioequivalence with the reference drug. The demonstration of bioequivalence guarantees not only that the generic drug contains the same active substance quantity, but it is also absorbed in the same manner than the reference drug. This methodology allows us to conclude that both drugs produce the same systemic effects. The lower price of a generic drug is due to several different factors, but none of them incur in differences in quality, since the manufacture of a generic drug follows identical requirements to those followed by the reference drug. "Prescribility", "interchangeability" and "drug substitution" policies are relevant concepts to discuss in the context of generic drugs use. In that sense, an approved generic drug can be prescribed with the same quality, efficacy and safety guaranties that those of the reference drug and both of them can be considered exchangeable. However, it is preferred to avoid any unnecessary drug substitutions in a patient chronic treatment (AU)
Asunto(s)
Humanos , Masculino , Femenino , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/epidemiología , Medicamentos Genéricos/uso terapéutico , Política de Medicamentos Genéricos , Medicamentos Genéricos/administración & dosificación , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/farmacocinética , Equivalencia TerapéuticaRESUMEN
BACKGROUND: Orodispersible tablets (ODTs) are tablet or wafer forms of medication that disintegrate in the mouth, aided only by saliva. ODTs rely on different fast dissolve/disintegration manufacturing technologies. OBJECTIVES: Disintegration time differences for several olanzapine ODT forms were investigated. Risperdal M-Tab(®) was included as a non-olanzapine ODT comparator. RESEARCH DESIGN AND METHODS: Eleven olanzapine ODT examples and orodispersible risperidone strengths were evaluated in vitro for formulation composition, manufacturing method, disintegration and dissolution characteristics, and formulation differences in comparison with freeze dried Zydis(®) ODT. Automated dissolution test equipment captured ODT dissolution rates by measuring real-time release of active ingredient. A high-speed video camera was used to capture tablet disintegration times in warm simulated saliva. MAIN OUTCOME MEASURE: The main outcome measure was the disintegration and dissolution characteristics of the ODT formulations. RESULTS: The ODT manufacturing method was associated with time to disintegrate; the fastest were freeze dried tablets, followed by soft compressed tablets and then hard/dense tablets. Olanzapine Zydis(®) was the only ODT that completely disintegrated in less than 4 s for all strengths (5, 10, 15, and 20 mg), followed by 5-mg Prolanz FAST(®) (12 s) and then risperidone ODT 4 mg (40 s). Reasons for slow dissolution of the olanzapine generics may include low product potency, excipient binding, excipient solubility, active ingredient particle size and incomplete disintegration. CONCLUSIONS: Differences in the formulation and manufacturing process of olanzapine ODTs appear to have a strong influence on the disintegration time of the active compound; differences that may potentially impact their use in clinical practice.
Asunto(s)
Antipsicóticos/química , Benzodiazepinas/química , Excipientes/química , Saliva Artificial/metabolismo , Antipsicóticos/administración & dosificación , Antipsicóticos/metabolismo , Benzodiazepinas/administración & dosificación , Benzodiazepinas/metabolismo , Química Farmacéutica , Relación Dosis-Respuesta a Droga , Medicamentos Genéricos/administración & dosificación , Medicamentos Genéricos/química , Medicamentos Genéricos/metabolismo , Humanos , Técnicas In Vitro , Olanzapina , Tamaño de la Partícula , Risperidona/química , Risperidona/metabolismo , Solubilidad , Comprimidos , Factores de Tiempo , Grabación en VideoRESUMEN
PURPOSE: The safety of converting kidney transplant recipients on brand-name tacrolimus to generic tacrolimus during hospitalization was evaluated. METHODS: A single-center observational study compared tacrolimus dosages and trough tacrolimus levels in kidney transplant recipients who had a kidney transplant more than 90 days before hospital admission. Patients in the "brand" group were maintained on brand-name tacrolimus throughout the entire study period. Patients in the generic group were maintained on brand-name tacrolimus before hospital admission, converted to the generic formulation during hospitalization, and returned to the brand-name product at discharge. Tacrolimus dosages were converted on a milligram-per-milligram basis and adjusted, if needed. Outcomes evaluated included the percentage of patients requiring a dosage change, absolute change in average tacrolimus trough level, and frequency of biopsy-proven acute rejection within six months of discharge. RESULTS: A total of 100 patients were evaluated for inclusion in the brand group, with 42 meeting study criteria; 98 patients were evaluated in the generic group, with 36 qualifying for the study. There were no significant differences between the brand and generic groups with respect to dosage adjustments required or trough tacrolimus levels at any point in the transition of care. Mean trough concentrations were similar between groups during all periods of care. The only occurrence of new-onset acute rejection within six months after admission occurred in the brand group. CONCLUSION: Substitution of a generic formulation of tacrolimus for the innovator product during hospitalization of kidney transplant recipients was safely implemented. Tacrolimus dosage adjustments were common throughout the transitions of care, regardless of the formulation used.
Asunto(s)
Medicamentos Genéricos/uso terapéutico , Hospitalización/tendencias , Inmunosupresores/uso terapéutico , Trasplante de Riñón/tendencias , Tacrolimus/uso terapéutico , Adulto , Anciano , Química Farmacéutica , Medicamentos Genéricos/metabolismo , Femenino , Rechazo de Injerto/sangre , Rechazo de Injerto/epidemiología , Rechazo de Injerto/prevención & control , Humanos , Inmunosupresores/sangre , Masculino , Persona de Mediana Edad , Tacrolimus/sangre , Resultado del Tratamiento , Adulto JovenRESUMEN
Pharmacists have an important role in detecting, preventing, and solving prescription problems, which if left unresolved, may pose a risk of harming the patient. Objective: The objectives of this study were to evaluate the feasibility of a generic study instrument for documentation of prescription problems requiring contact with prescriber before dispensing. The study was organized: 1) by countries: Estonia, Norway and Sweden; 2) by type of prescriptions: handwritten prescriptions, printouts of prescriptions in the electronic medical record and electronically transmitted prescriptions to pharmacies; and 3) by recording method - self-completion by pharmacists and independent observers. Methods: Observational study with independent observers at community pharmacies in Estonia (n=4) and Sweden (n=7) and self-completed protocols in Norway (n=9). Results: Pharmacists in Estonia contacted the prescriber for 1.47% of the prescriptions, about 3 times as often as in Norway (0.45%) and Sweden (0.38%). Handwritten prescriptions dominated among the problem prescriptions in Estonia (73.2%), printouts of prescriptions in the electronic medical record (89.1%) in Norway and electronically transmitted prescriptions to pharmacies (55.9%) in Sweden. More administrative errors were identified on handwritten prescriptions and printouts of prescriptions in the electronic medical record in Estonia and in Norway compared with electronically transmitted prescriptions to pharmacies in Sweden (p<0.05 for prescription types and p<0.01 for countries). However, clinically important errors and delivery problems appeared equally often on the different types of prescriptions. In all three countries, only few cases of drug interactions and adverse drug reactions were identified. Conclusion: Despite the different patterns of prescription problems in three countries, the instrument was feasible and can be regarded appropriate to document and classify prescription problems necessitating contact with prescriber before dispensing, irrespective of the type of prescription or recording method (AU)
Los farmacéuticos juegan un papel importante en la detección, prevención y resolución de problemas de prescripción, que si no se resuelven pueden poner en riesgo de daño al paciente. Objetivo: Los objetivos de este estudio fueron evaluar la factibilidad de un instrumento de genérico de estudio para documentar los problemas de prescripción que requieren contactar al prescriptor antes de dispensar. El estudio se organizó: 1) por países: Estonia, Noruega y Suecia; 2) por tipo de recetas: recetas manuscritas, recetas impresas desde el historial electrónico del médico, y prescripción electrónica; y 3) por método de registro: auto-cumplimentación por los farmacéuticos o por observadores independientes. Métodos: Estudio observacional con observadores independientes en las farmacias comunitarias en Estonia (n=4) y Suecia (n=7) y protocolos autocumplimentados en Noruega (n=9). Resultados: Los farmacéuticos en Estonia contactaron a los prescriptores en el 1.47% de las recetas, unas 3 veces más frecuentemente que en Noruega (0.45%) y Suecia (0.38%).Las recetas manuscritas dominaron entre los problemas de prescripción en Estonia (73.2%), las impresiones de recetas desde el historial electrónico (89.1%) en Noruega, y las prescripciones electrónicamente transmitidas a las farmacias (55.9%) en Suecia. Se identificaron más errores administrativos en las recetas manuscritas y en las impresas desde el historial electrónico en Estonia y Noruega, comparadas con las electrónicamente transmitidas a la farmacia de Suecia (p<0.05 para los tipos de recetas y p<0.01 para los países). Sin embargo, los errores clínicamente importantes y los problemas de entrega aparecieron igualmente entre los diferentes tipos de recetas. En los tres países, se identificaron unos pocos casos de interacciones medicamentosas y de reacciones adversas. Conclusión: A pesar de los tres patrones diferentes de prescripción en los tres países, el instrumento fue factible y puede considerarse apropiado para documentar y clasificar los problemas de prescripción que necesitan contactar con el prescriptor antes de ser dispensados, independientemente del tipo de receta o del método de registro (AU)
Asunto(s)
Humanos , Masculino , Femenino , Medicamentos Genéricos/uso terapéutico , Errores de Medicación/estadística & datos numéricos , Errores de Medicación/tendencias , Prescripciones de Medicamentos/normas , Farmacias/organización & administración , Farmacéuticos/ética , Farmacéuticos/normas , Seguridad del Paciente/legislación & jurisprudencia , Seguridad del Paciente/normas , Medicamentos Genéricos/metabolismo , Errores de Medicación/ética , Estonia/epidemiología , Noruega/epidemiología , Suecia/epidemiologíaRESUMEN
The aim of this study was to evaluate the weight uniformity of commonly divided tablets produced by Palestinian Pharmaceutical Companies and to evaluate the importance of both patient- and formulation-related variables on the splitting results. Eighty-four volunteers were enrolled in this study; their age, gender and occupation were documented in order, and the effect of these variables on the tablet splitting results was evaluated. Each volunteer was asked to divide six scored tablets of each product tested and was given clear instructions on how to conduct the splitting process. The split units were individually weighed and the RSD for each product was calculated as instructed in the European Pharmacopoeia (Ph. Eur. 5.5). Only one scored tablet product passed the Ph. Eur. test of mass uniformity, while the remaining 13 products failed; this indicates that the splitting of these tablet products is not a reliable means for the provision of accurate doses to patients. Age, gender and occupation of volunteers were not found to be predictive of any variability noted in the splitting results. The only factors that were suspected to be linked to passing the splitting test, as per the European Pharmacopoeia, were the shape, friability and hardness of the tablets. As a result of this study, we believe that the practice of dividing tablets, which should provide therapeutic and economic benefits for the patient, may potentially cause significant problems, especially in drugs with low therapeutic indices. Tablets produced by Palestinian Pharmaceutical Companies should comply with the new Ph. Eur. splitting regulations to reduce this potential for complications.
Asunto(s)
Composición de Medicamentos/métodos , Industria Farmacéutica , Preparaciones Farmacéuticas/normas , Farmacopeas como Asunto , Comprimidos , Adulto , Medicamentos Genéricos/metabolismo , Medicamentos Genéricos/normas , Femenino , Adhesión a Directriz , Guías como Asunto , Dureza , Humanos , Masculino , Persona de Mediana Edad , Preparaciones Farmacéuticas/metabolismo , Adulto JovenRESUMEN
BACKGROUND: The Internet has become a popular source of health information. However, there is little information on what drug information and which Web sites are being searched. OBJECTIVE: To investigate the sources of online information about prescription drugs by assessing the most common Web sites returned in online drug searches and to assess the comparative popularity of Web pages for particular drugs. METHODS: This was a cross-sectional study of search results for the most commonly dispensed drugs in the US (n=278 active ingredients) on 4 popular search engines: Bing, Google (both US and Canada), and Yahoo. We determined the number of times a Web site appeared as the first result. A linked retrospective analysis counted Wikipedia page hits for each of these drugs in 2008 and 2009. RESULTS: About three quarters of the first result on Google USA for both brand and generic names linked to the National Library of Medicine. In contrast, Wikipedia was the first result for approximately 80% of generic name searches on the other 3 sites. On these other sites, over two thirds of brand name searches led to industry-sponsored sites. The Wikipedia pages with the highest number of hits were mainly for opiates, benzodiazepines, antibiotics, and antidepressants. CONCLUSIONS: Wikipedia and the National Library of Medicine rank highly in online drug searches. Further, our results suggest that patients most often seek information on drugs with the potential for dependence, for stigmatized conditions, that have received media attention, and for episodic treatments. Quality improvement efforts should focus on these drugs.